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Introduction
Hughes-Stovin Syndrome (HSS) is a very rare clinical
disorder characterized by pulmonary artery aneurysms
and peripheral venous thrombosis. Typical symptoms
are recurrent fever, chills, haemoptysis and it usually
affects young men. The natural course of the illness is
usually fatal because of fulminant haemoptysis. The
aetiology of Hughes-Stovin syndrome is still unknown;
however it is supposed to be a clinical variant manifesta-
tion of Behçet disease.
Objectives
While several case reports have shown infliximab to be
efficacious in patients with Behçet’s syndrome and pul-
monary arterial aneurysm, no experience exists about
it’s use in Hughes Stovin Syndrome.
Methods
In the present report we describe the first successful use
of infliximab in refractory Hughes Stovin Syndrome.
Results
A 12-year-old albanian boy was first admitted to local a
Children Hospital with fever, diplopia, headache and
repeated vomiting lasting for weeks. There was no prior
medico-surgical illness history. Cerebral MRI (magnetic
resonance imaging) revealed thrombosis of right sigmoid
and transverse sinuses. Acetyl salicylic acid treatment
was started and the boy was discharged. Shortly theraf-
ter he started complaining high fever and left leg pain.
Computed tomography (CT) angiography revealed a
right femoral artery pseudoaneurysms. Echocardiography
showed a large tricuspid valve vegetation. In the suspi-
cion of bacterial endocarditis antibiotic therapy was
instituted, without improvement of symptoms. Because
of refractory fever the boy was so referred to our
Children Hospital. Inflammatory markers were markedly
elevated. Echocardiography confirmed the presence of a
tricuspid valve vegetation and detected a large atrial
thrombus. The boy was put in heparin and referred to a
Cardiothoracic Surgery Department, where cardiac
thrombus and vegetations were surgically removed.
Nevertheless, fever persisted. Thoracic angio-CT-scan
was so performed, that showed three partially throm-
bosed aneurysms of right segmental pulmonary arteries.
On the basis of pulmonary artery aneurysms, sinus
thromboses and femoral pseudoaneurysm a diagnosis of
Hughes-Stovin syndrome was made. HLA B-51 allele
was detected. There where no other findings consistent
with Behçet disease. Pulse intravenous cyclophospha-
mide plus oral prednisone was started with prompt
amelioration of symptoms and disappearance of fever.
Antiaggregation and coagulation were discontinued to
avoid the risk of hemoptysis. Two months thereafter
pulmonary aneurysms resulted only partially reduced
and inflammatory markers were still slightly elevated.
Episodes of relapsing remitting fever occurred. His treat-
ment was so changed to intravenous infliximab with
methotrexate to which he showed an excellent response
with complete regression of aneurysms at contrast
enhanced pulmonary MRA and normalization of inflam-
matory markers. This permitted successful and quick
steroid tapering.
Conclusion
Anti-TNF inhibitors should be considered in patients
affected by Huges Stovin Syndrome who do not respond
to treatment with corticosteroids and cyclophosphamide.
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